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Edited by Christos StournarasAbstract Rho GTPases contribute to multiple cellular pro-
cesses that could aﬀect cancer progression, including cytoskeletal
dynamics, cell cycle progression, transcriptional regulation, cell
survival and vesicle traﬃcking. In vitro several Rho GTPases
have oncogenic activity and/or can promote cancer cell invasion,
and this correlates with increased expression and activity in a
variety of cancers. Conversely, other family members appear
to act as tumour suppressors and are deleted, mutated or down-
regulated in some cancers. Genetic models are starting to provide
new information on how Rho GTPases aﬀect cancer development
and progression. Here, we discuss how Rho GTPases could con-
tribute to diﬀerent steps of cancer progression, including prolif-
eration, survival, invasion and metastasis.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Rho GTPases form a distinct family within the Ras-like pro-
tein superfamily, which also includes the Ras, Rab, Arf and
Ran families (Fig. 1). Rho members diﬀer from other Ras-like
GTPases by the presence of a Rho-speciﬁc insert domain. Rho
proteins are highly conserved from lower eukaryotes to plants
and mammals [1]. In mammals the family comprises 20 mem-
bers, divided into 8 diﬀerent subfamilies (Figs. 1 and 2). Splice
variants of Rac1 and Cdc42 have also been identiﬁed. Rho-
BTB3 and Miro1 and 2 are now considered as outside of the
Rho family because they lack a proper Rho insert domain
and are of distinct phylogenetic origin [1].
Most Rho family members act as molecular switches, cycling
between a GTP-bound active form and a GDP-bound inactive
form [2] (Fig. 3). Their activity is increased by guanine nucle-
otide exchange factors (GEFs), which promote the release of
bound GDP and subsequent binding of the more abundant
GTP, and downregulated by GTPase-activating proteinsAbbreviations: ECM, extracellular matrix; JNK, Jun N-terminal
kinase; MLC, myosin light chain; MMP, matrix metalloproteases;
PAK, p21-activated kinase; PKA, cAMP-dependent protein kinase;
ROCK, Rho-associated, coiled-coil containing protein kinase
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teins are also frequently post-translationally modiﬁed at the
C-terminus with the addition of a lipidic group by prenylation
(farnesylation or geranylgeranylation) or palmitoylation,
thereby enhancing their interaction with membranes. GDI
proteins (guanine–nucleotide-dissociation inhibitors) also reg-
ulate the activity of Rho GTPases by binding to the C-terminal
prenyl group, preventing their membrane association and
sequestering them in the cytoplasm, and thus frequently inhib-
iting their access to downstream targets [4]. RhoGDIs can bind
to either the GTP- or the GDP-loaded forms. To date over 70
RhoGEFs, 60 RhoGAPs and 3 RhoGDIs have been identiﬁed
in mammals, reﬂecting the complexity of the regulation of this
class of proteins.
The Rho family members Rnd1, Rnd2, Rnd3/RhoE, RhoH,
RhoBTB1 and RhoBTB2 have key amino acid substitutions
that make them lack GTP hydrolysis activity and GDP bind-
ing and they are therefore permanently bound to GTP [5,6]
(Fig 2). These proteins are likely to be regulated by expression
level, phosphorylation or protein interactions through speciﬁc
protein domains. Phosphorylation regulates the activity and
localization of RhoA and Rnd3/RhoE, which are phosphory-
lated by cAMP-dependent protein kinase (PKA) and Rho-
associated, coiled-coil containing protein kinase (ROCK),
respectively [7,8].
Once activated, Rho GTPases bind diﬀerent eﬀector mole-
cules and trigger a signalling cascade to direct cellular re-
sponses. Rho GTPases have been implicated in many cellular
processes including actin and microtubule cytoskeleton
organization, cell division, motility, cell adhesion, vesicular
traﬃcking, phagocytosis and transcriptional regulation [2].
Considerable insight into their function has come from the
study of model organisms. Dictyostelium discoideum has more
than 15 genes in the family including members of the Rac
and RhoBTB subfamilies but not the other human subfamilies.
Several Rac isoforms aﬀect migration and cytokinesis [9]. The
nematode Caenorhabditis elegans has six members, including
Rho, Rac and Cdc42. They are required for cytoskeleton-based
processes including cell migration, cell polarity, phagocytosis,
spindle formation, axon guidance, locomotion and embryonic
development [10]. Drosophila melanogaster has seven members
including Rho, 3 Rac isoforms, Cdc42 and RhoBTB, which
have been shown to aﬀect cell shape, morphology, polarity, cell
division, and the maintenance of epithelial architecture.
As well as contributing to physiological processes, Rho
GTPases have been found to contribute to pathological pro-
cesses including cancer cell migration, invasion, and metasta-
sis, inﬂammation, and wound repair [2,5]. In this review, weblished by Elsevier B.V. All rights reserved.
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Fig. 1. Phylogenetic tree showing the mammalian Ras GTPase superfamily. The 20 Rho GTPase family members are grouped into eight subfamilies.
Miro proteins and RhoBTB3 form independent branches within the superfamily, separate from the Rho GTPases.
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processes that contribute to cancer progression.2. Steps in cancer progression
Rho GTPases have been reported to contribute to most
steps of cancer initiation and progression including the acqui-
sition of unlimited proliferation potential, survival and evasion
from apoptosis, tissue invasion and the establishment of
metastases.
Primary tumours generally arise as a consequence of multi-
ple mutations and epigenetic changes aﬀecting key genes that
ultimately aﬀect proliferation and survival. Activating muta-
tions in the three Ras isoforms, Ki-Ras, N-Ras and Ha-Ras,
are found in 15% of all human tumours. In contrast, Rho pro-
teins are only rarely mutated in tumours, whereas their expres-
sion and/or activity are frequently altered. For example,
several Rho GTPases are upregulated in some human tu-
mours, including RhoA, RhoC, Rac1, Rac2, Rac3, Cdc42,
Wrch2/RhoV and RhoF [11–13].
Uncontrolled proliferation, coupled to increased survival
signals that permit tumour cells to escape from apoptosis, re-
sult in tumour growth. Some Rho GTPases stimulate cell cycle
progression and regulate gene transcription, and this could in
part explain their pro-oncogenic properties, for example inpromoting Ras-induced transformation [14]. The induction
of tumour vascularisation is essential for tumours to grow be-
yond a certain size and malignant cells release factors that pro-
mote angiogenesis from nearby pre-existing blood vessels.
Some Rho GTPases are thought to be able to regulate the re-
lease of pro-angiogenic factors to promote neovascularisation
[15].
Invasion of epithelial cancers is initiated when the integrity
of the epithelium is disrupted and malignant cells disrupt the
basement membrane and enter the underlying stroma
(Fig. 4). This normally implies loosening of epithelial cell–cell
contacts and acquisition of a more motile phenotype in a pro-
cess frequently referred as epithelial to mesenchymal transition
(EMT). Invasive epithelial cancer cells often have reduced
expression of the cell–cell adhesion protein E-cadherin and
start expressing markers of mesenchymal origin such as vimen-
tin and N-cadherin [16]. Non-epithelial cancers also invade so-
lid tissues [17].
Cancer cells can invade into tissues either as single cells or as
cell groups (collective cell migration) (Fig. 5). Single cells have
been described to use two alternative migratory mechanisms:
mesenchymal and amoeboid migration. Cells using mesenchy-
mal migration have an elongated morphology and extend long
protrusions at the front. Integrin-based adhesions and strong
traction are the driving forces for movement in addition to
extracellular matrix (ECM) degradation by secreted and/or
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Fig. 2. Domain organization of the Rho GTPases. RhoA, RhoB, RhoC, Rac1, Rac2, Rac3, RhoG, RhoD, RhoF, Cdc42, TCL and TC10 have a
similar basic protein structure. Rnd1, Rnd2, Rnd3/RhoE and RhoH are considered atypical Rho GTPases that have modiﬁcations in the GTP/GDP
binding region that make them lack GTPase activity. Wrch1 and Wrch2 are characterized by the presence of a N-terminal proline-rich region.
RhoBTB1 and 2 have the most divergent protein organization with two characteristic BTB domains NLS, nuclear localisation sequence.
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F.M. Vega, A.J. Ridley / FEBS Letters 582 (2008) 2093–2101 2095transmembrane proteases [17]. In contrast, amoeboid migra-
tion is generally independent of extracellular protease activity
and is driven by actomyosin-based cortical contraction, and
cells have a more rounded shape. In collective cell invasion,
cells move in groups through the extracellular matrix andmaintain cell–cell adhesions. A leading cell at the tip of the
group generates the migratory traction necessary for move-
ment and the cells at the back and middle of the group are
mostly dragged passively. Degradation of the ECM by matrix
metalloproteases (MMPs) is essential for this kind of collective
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Fig. 4. Schematic model showing the potential roles of diﬀerent Rho GTPases during various stages in cancer progression. See text for references.
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Fig. 5. Rho GTPases in tumour cell invasion. Diﬀerent mechanisms of cancer cell invasion and the possible roles of some Rho GTPases are depicted.
See text for references.
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migration to another depending on conditions [17,18].
To establish metastases in distant tissues, tumour cells have
to enter the vascular or lymphatic system, then exit it and pro-
liferate in the new tissue. The ability of Rho GTPase family
members to regulate cytoskeletal dynamics, cell adhesion and
cell migration [2] points to a central role in cancer cell invasion
and metastasis. The possible roles of the diﬀerent Rho GTPas-
es in diﬀerent steps of cancer progression are discussed below.
2.1. Rho subfamily
The Rho subfamily consists of the highly conserved RhoA,
RhoB and RhoC proteins (Fig. 1). RhoA and RhoC expres-sion and/or activity is frequently increased in human tumours
[12,19], whereas RhoB is often downregulated [12].
RhoA has been implicated in virtually all stages of cancer
progression. RhoA might play a role during tumour cell prolif-
eration and survival: for example, in vitro, constitutively active
RhoA can stimulate transformation [2]. In normal epithelia,
RhoA contributes to the generation of epithelial polarity and
junction assembly and function (reviewed in [20]) but also af-
fects epithelial disruption during tumour progression. Rho
activity can be inhibited downstream of cadherins leading to
a more motile phenotype [21]. Diﬀerent GEFs and GAPs inﬂu-
ence how Rho proteins can act in diﬀerent contexts either pro-
moting epithelial organization and polarity or epithelial EMT,
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[22].
RhoA is important for both amoeboid and mesenchymal
migration (Fig. 4). RhoA-ROCK signalling is proposed to in-
duce actomyosin-based cortical contractility leading to amoe-
boid migration via blebbing, as well as tail retraction in
mesenchymal migration [17]. A 3D in vitro invasion model
using co-cultures of SSC12 carcinoma cells, that have not
undergone a complete mesenchymal transformation retaining
some epithelial markers, with stromal ﬁbroblasts has shown
how a ﬁbroblast is the leading cell in this model of collective
cell invasion [23]. This ﬁbroblast generates the traction force
and remodels the matrix through MMPs. Diﬀerent Rho GTP-
ases were found to be required in the leading ﬁbroblast and the
following carcinoma cells with a RhoA regulation of Myosin
light chain (MLC) in the former and mainly Cdc42 and
MRCK function in the latter. Rho GTPases can also regulate
the production of MMPs, aﬀecting matrix remodelling and tu-
mour cell invasion. Rho can induce the expression or secretion
of MMPs [24]. Nevertheless, studies on cells depleted of RhoA
by RNAi are variable and show a strong dependence of cell
background for its eﬀect on migration and invasion [25,26]
In contrast to RhoA, RhoC has no apparent transforming
activity and the involvement of RhoC in cancer progression
appears to be restricted largely to metastasis [27]. RhoC was
identiﬁed in a screen for genes upregulated in melanoma
metastases [28], and has subsequently been proposed as a mar-
ker for poor prognosis in cancers of diﬀerent origins [29]. In-
creased RhoC expression has been claimed as the possible
cause for the induction in invasion and metastasis triggered
by the overexpression of the microRNA-10b in breast cancer
[30]. Studies of RhoC knock-out mice show that RhoC is dis-
pensable for embryogenesis and tumour initiation but is re-
quired for metastasis [27]. RhoC expression is increased
during EMT in a colon cancer model and contributes to
EMT-induced migration, whereas RhoA levels go down [25].
Knockdown of RhoC expression by RNAi conﬁrms that
RhoC is important for invasion in vitro [25,26,31]. It is not
yet clear how RhoC increases invasion and metastasis or
why its eﬀects diﬀer from RhoA.
Some reports indicate that RhoA, RhoC and their down-
stream target ROCK are needed for cancer cell extravasation,
but these studies are largely based on chemical inhibitors that
are not completely speciﬁc [32]. Interestingly, RhoC can induce
the production of angiogenic factors in breast cancer, and this
could help promote entry into blood vessels and thereby
metastasis [15]. More extensive work is needed to elucidate
the possible contribution of Rho GTPases to the extravasation
of cancer cells.
Unlike RhoA and RhoC, RhoB is often downregulated in
human tumours and its expression inversely correlates with tu-
mour aggressiveness [33]. It has been proposed that RhoB can
work as a tumour suppressor as it is activated in response to
several stress stimuli including DNA damage or hypoxia,
and it has been reported to inhibit tumour growth, cell migra-
tion and invasion and have proapoptotic functions in cells [33].
RhoB knock-out mice develop normally but have enhanced
carcinogen-induced skin tumour formation, in agreement with
a role of RhoB as a tumour suppressor [34]. RhoB also sup-
presses invasion: for example it has been postulated to act
downstream of PKCs in the regulation of cancer cell invasionin vitro [35] and it was also reported to inhibit Ras-induced
invasion and metastasis [36].
The exact mechanism whereby RhoB suppresses tumour
growth and invasion is not clear, although its role in endo-
somal traﬃcking could be important. RhoB regulates the
delivery of signalling proteins, including growth factor recep-
tors and the tyrosine kinase Src, to speciﬁc intracellular com-
partments [37], and this could certainly inﬂuence
proliferation and invasion.
2.2. Rac subfamily
The Rac subfamily of Rho GTPases comprises Rac1, Rac2,
Rac3 and RhoG (Fig. 1). Rac1 is over-expressed in various
tumours and accumulating evidence indicates that Rac1-
dependent cell signalling is important for malignant transfor-
mation [12]. Rac1 is one of the few Rho GTPases mutated in
some tumours, with mutations mainly aﬀecting the eﬀector do-
main that interacts with downstream targets. It was proposed
that these mutations could increase the activity of the protein
and the survival of the tumours [38].
A splice variant of Rac1, Rac1b, has an extra intron close to
the GTP-binding region. It was initially identiﬁed to be upreg-
ulated in colon cancers [39]. It does not bind RhoGDI and
thus is present predominantly in the GTP-bound state.
Although Rac1b is defective in activating several Rac1-regu-
lated signalling pathways, in some cell types it stimulates cell
survival and cell cycle progression through NFjB, and is less
susceptible to ubiquitination and degradation, which could ex-
plain its increased expression in cancers [40–42].
So far little is known about the role of Rac proteins in cancer
progression in vivo. Rac1 knock-out in mice is embryonic
lethal [43] but conditional knock-out mice have been studied
extensively [44,45]. In a conditional lung cancer mouse model
Rac1 function was required for K-Ras-driven proliferation
and tumorigenicity [46]. Similarly, mice lacking the Rac-spe-
ciﬁc GEF Tiam1 are protected from Ras-induced skin cancer,
developing fewer tumours, although the tumours that do form
are more aggressive [47]. These results suggest that Rac pro-
teins normally stimulate tumour cell proliferation but inhibit
tumour dissemination.
Rac1 could contribute to cancer cell proliferation via regula-
tion of the cell cycle: for example, it stimulates expression of
cyclin D1, and induces cell transformation in vitro [2,14]. It
is likely to inhibit cancer invasion through its ability to en-
hance epithelial cell-cell adhesion. However, active Rac can
mediate the loss of adherens junction in some situations, pro-
moting a more migratory phenotype, and thus Rac could pro-
mote or inhibit tumour cell invasion depending on the cell
background [48–51]. Rac is necessary for the generation of
lamellipodial protrusions during mesenchymal migration, as
well as for the amoeboid migration of Ras-transformed cells
(Fig. 5)[17]. Rac1 can also contribute to cancer cell invasion
by regulating the production of MMPs and their natural inhib-
itors, the Tissue-speciﬁc inhibitors of MMP (TIMPs) [24].
Like Rac1, Rac2 and Rac3 are over-expressed in some tu-
mours. Rac3 is hyperactive and/or deregulated in breast can-
cers [19,52,53]. The contribution of diﬀerent Rac isoforms to
migration is likely to depend on the cell type and their relative
expression levels. Rac2 is required for neutrophil migration
but whether it acts similarly in tumours is not known [54]. In
contrast, Rac1 and Rac2 are dispensable for cell migration
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Studies of Rac3-null mice indicate that Rac3 but not Rac1
or Rac2 speciﬁcally contributes to the development of Brc-
Abl-induced lymphomas in vivo [56]. However, in ﬁbroblasts,
Rac1 but not Rac3 suppression by RNAi aﬀects lamellipodium
formation although cell invasion is reduced in both cases [57].
It is not yet clear how these results can be translated to cancer
cell invasion in vivo.
Little is known about the role of RhoG in cancer, although
it induces actin reorganization and cell migration via Rac
in vitro [58], and thus it will be interesting to determine its role
in cancer cell invasion.
2.3. Cdc42 subfamily
Cdc42 and the closely related RhoQ/TC10 and RhoJ/TCL
form a distinct subfamily of Rho GTPases. Cdc42 expression
is upregulated in some breast cancers [59], yet liver-speciﬁc
knock-out indicates that loss of Cdc42 enhances liver cancer
development [60], suggesting that the contribution of Cdc42
to cancer progression may be tissue-speciﬁc. This could reﬂect
the multiple roles of Cdc42 in regulating cell polarity as well as
cell cycle progression.
Both Cdc42 and RhoQ/TC10 stimulate transformation and
contribute to Ras-induced transformation in vitro
[2,12,14,61], and for Cdc42 this has been suggested to be due
to its eﬀect on receptor traﬃcking and degradation [62].
RhoQ/TC10 is also implicated in receptor traﬃcking, particu-
larly of the glucose transporter [63], but whether this accounts
for its role in transformation is not known. Another mecha-
nism whereby Cdc42 could aﬀect cell cycle progression is by
regulating chromosome segregation during mitosis: only
Cdc42 knockdown out of all Rho GTPases was found to in-
duce chromosome misalignment during cell division, leading
to multinucleate cells. RhoJ/TCL and RhoQ/TC10 enhance
this eﬀect when suppressed in conjunction with Cdc42 [64],
pointing towards a possible redundancy in function of Cdc42
family proteins during spindle formation and cell division.
Cdc42 is involved in the establishment of normal epithelial
polarity as well as migratory polarity via its interaction with
the Par3/Par6/aPKC polarity complex, which in turn regulates
Rac via Tiam1 [20]. Cdc42 is thus predicted to inhibit invasion
by promoting epithelial polarity, yet conversely also stimulate
migration. Indeed, it contributes to cancer cell invasion in sin-
gle cells in vitro with a mesenchymal morphology although
probably not with an amoeboid morphology [17,65]. It is also
important for collective cancer cell invasion, where it acts
through its target MRCK to stimulate actomyosin contractil-
ity [23] (Fig. 5). However, whether the Par3/Par6/aPKC com-
plex is also involved in these processes is not yet known.
2.4. Wrch1 and Wrch2
Wrch1/RhoU and Wrch2/RhoV, also known as Chp, both
have an N-terminal proline-rich domain that is not present in
other Rho family members (Fig. 2), and which can bind to
SH3 domain-containing proteins such as Nck2 and Grb2 [5].
Wrch1 is upregulated by the Wnt signalling pathway, and thus
could be involved in Wnt-driven oncogenic transformation
[66]. It can be upregulated or downregulated in some primary tu-
mours [5,67], but it is not knownwhether this correlateswith lev-
els of Wnt signalling. Wrch1 stimulates cell cycle progression,
and constitutively activeWrch1 is able to induce transformationof ﬁbroblasts when overexpressed [66,67]. It is therefore possible
thatWnt-inducedWrch1 expression contributes to cancer devel-
opment by stimulating proliferation, although how it does this
remains to be established.
Wrch2 is abundant in cancer cell lines and upregulated in
some human cancers [11]. It diﬀers from Wrch1 at the C-termi-
nus: it lacks a CAAX box and instead has a unique 32 amino
acid sequence (Fig. 2). It has been reported to stimulate the
Jun N-terminal kinase (JNK) signalling pathway [11] but the
relevance of this to cancer progression is not known.
Overexpression of Wrch1 and Wrch2 induces actin cytoskel-
etal reorganization including formation of ﬁlopodia and disso-
lution of stress ﬁbers. Whether this reﬂects their physiological
function or is just a consequence of sequence similarity to
Cdc42 is not known, although, in the case of Wrch1, it does
not bind to the Cdc42 eﬀectors WASP or p21-activated kinase
(PAK) [63]. However, Wrch interaction with Nck2 could allow
them to recruit these proteins indirectly and thereby promote
cell migration [68]. Future studies should delineate in more de-
tail whether and how Wrch proteins contribute to cancer pro-
gression.
2.5. Rnd proteins
The Rnd (Round) proteins, Rnd1, Rnd2 and Rnd3/RhoE,
received their name for the rounded morphology and loss of
stress ﬁbers observed in cells overexpressing Rnd1 or Rnd3.
The three Rnd genes are regulated at the transcriptional level
in response to a variety of stimuli. Rnd1 has been implicated
in axon guidance and Rnd2 in neurite outgrowth and cytokine-
sis, but it is only Rnd3/RhoE that has been clearly linked to
functions related with cancer progression [6].
Rnd3/RhoE has been reported to be downregulated in pros-
tate cancer yet upregulated in other tumours [69,70]. The levels
of Rnd3/RhoE in diﬀerent tumours could reﬂect the fact that it
is a p53-inducible gene and is induced by genotoxic stress [71].
Rnd3/RhoE could on the one hand suppress cancer cell prolif-
eration since it can inhibit cell cycle progression and Ras-in-
duced transformation, yet on the other hand it could
enhance cancer progression by acting as a pro-survival factor
[69,71,72]. Its eﬀect would therefore depend on the cellular
background.
Rnd3/RhoE also aﬀects epithelial polarity and cell migra-
tion. Overexpression of Rnd3/RhoE in epithelial cells stimu-
lates multilayering [20], which would be expected to enhance
invasion. It also increases the migration speed of epithelial cells
[6]. Given these multiple functions of Rnd3/RhoE on cell cycle,
survival and morphology, it will be interesting to know how it
aﬀects diﬀerent steps of cancer progression in vivo.
2.6. RhoD and RhoF/Rif
RhoD and RhoF have not so far been implicated in cancer
cell proliferation or survival, but both of them can aﬀect cell
morphology. Overexpression of RhoF induce the generation
of abundant long actin-rich Cdc42-independent ﬁlopodia and
a moderate increase in stress ﬁbers, but the relevance of these
changes for cell migration and physiology is unknown [73].
Interestingly, RhoF is upregulated in malignant B-cell lympho-
mas [13]. Whether this overexpression leads to a change in
adhesion or migration of lymphoma cells is not yet known.
RhoD regulates vesicle traﬃcking between intracellular
compartments and endosomal motility [63]. RhoD can also in-
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stress ﬁbers, focal adhesion disassembly and actin-based pro-
trusions at the plasma membrane, resulting in an inhibition
of cell motility in some cases. The link between these two
RhoD-regulated responses is so far speculative, but intracellu-
lar traﬃcking can mediate the delivery of signalling proteins to
the plasma membrane aﬀecting the formation of functional
complexes that drive migration. No link so far has been found
between cancer progression and RhoD expression.
2.7. RhoH
RhoH is frequently rearranged or mutated in B-cell lympho-
mas, and this is believed to contribute to lymphoma progres-
sion [5,74]. Consistent with this, RhoH knock-out mice show
several deﬁciencies in T-cells [75]. Knockdown of RhoH by
RNAi stimulates proliferation, survival and migration of
hematopoietic progenitor cells [76]. Although RhoH by itself
does not seem to exert a signiﬁcant eﬀect on actin reorganiza-
tion, recent work places RhoH function as antagonistic to
Rac1 in primary hematopoietic precursor cells: RhoH impairs
migration, chemotaxis and cortical F-actin assembly by sup-
pressing Rac1 activation and membrane targeting. Conversely,
cells lacking RhoH have enhanced Rac1 activity and migration
[77]. How RhoH regulates Rac1 at a molecular level is not yet
known. Previous observations showed that RhoH can also in-
hibit NFjB and p38 activation by other Rho GTPases [78],
suggesting that it may act to regulate multiple Rho family
members. It is possible that this inhibitory eﬀect of RhoH on
Rac1 explains how loss of RhoH function by mutation con-
tributes to malignant progression in lymphomas, since Rac1
has been implicated in lymphoma progression [79], although
other mechanisms cannot be ruled out as the physiological
function of RhoH has not been comprehensively studied.
2.8. RhoBTB subfamily
RhoBTB1 and RhoBTB2 (also known as deleted in breast
cancer-2, DBC2) have an unusual domain structure, which in-
cludes an N-terminal GTP-binding domain followed by a pro-
line-rich region and two BTB domains (Fig. 2). RhoBTB
proteins have been suggested to be tumour suppressors, since
RhoBTB2 was identiﬁed as a gene homozygously deleted in
some breast and head and neck cancers and almost 50% of
breast cancer cell lines [80]. RhoBTB1 has also recently been
found to be deleted in some cancers, and in rare cases they
are mutated with loss of function [81]. However, they have also
been reported to be upregulated in some cancer cell lines [82].
Since very little is known of the molecular functions of Rho-
BTB proteins, it is only possible to speculate on their roles
in cancer in vivo. RhoBTB2 is a substrate of cullin3-dependent
ubiquitin ligase, and is implicated in the recruitment of cullin3,
which promotes the ubiquitination and degradation of sub-
strates implicated in cancer. RhoBTB2 might also regulate cell
cycle progression and/or apoptosis as a target of the E2F1
transcription factor [83].3. Rho regulators in cancer
The spatiotemporal activation of RhoGTPases is determined
by which GEFs andGAPs are involved, and in turn these GEFs
and GAPs can often act as scaﬀolds to bring the Rho GTPasesand other signalling proteins together with their downstream
targets [3]. This could explain the diﬀerent, or even opposite in
some cases, functions of closely related RhoGTPases in various
aspects of cancer progression, for example RhoA versus
RhoB.
Deregulation of expression or activity of some GEFs, GAPs
and eﬀector proteins has been observed in cancer. For exam-
ple, Vav proteins are GEFs for Rac and probably other Rho
proteins and have been described to have oncogenic properties.
They are implicated in a variety of human malignancies such
as neuroblastoma, melanoma, pancreatic tumours and leukae-
mia, although the oncogenic form has not been detected in hu-
man tumours [84]. The RhoGAP ARHGAP8 is frequently
upregulated in colon and cervical tumours [85] and RhoGDIa
expression is deregulated in various cancers [86]. Furthermore,
eﬀectors such as PAK and ROCK, downstream of Rac/Cdc42
and Rho, respectively, are upregulated in some cancers [87,88].
It is not clear how the altered expression of these various pro-
teins inﬂuences Rho GTPase function in cancer and indeed
whether the connection between these upregulated proteins
and their partner Rho GTPases is relevant for tumour progres-
sion. Further studies analysing the consequences of these
expression changes on Rho protein activity and also the spec-
iﬁcity between diﬀerent regulators, Rho isoforms and eﬀectors
will help to elucidate the particular functions of these proteins
in the various steps of cancer progression.4. Conclusions and perspective
RhoGTPases are involved in all stages during cancer progres-
sion. Although their initial discovery as regulators of cytoskele-
ton dynamics implied that they are most likely to contribute to
cancer cell migration and invasion, it is now clear that the func-
tion of Rho GTPases is not restricted to these events and that
they can aﬀect tumour cells through modulation of gene tran-
scription, cell division and survival, intracellular transport of
signalling molecules or modifying the interaction of cancer cells
with surrounding stromal cells. This makes the detailed analysis
of how Rho GTPases work in cells and contribute to tumours
very complex but at the same time promising for potential future
therapeutical intervention. The involvement of speciﬁc GEFs or
GAPs in deﬁned processes regulated by Rho GTPases makes
them particularly suitable as therapeutic targets [89].
Genetic models are so far available only for some of the Rho
GTPases, including RhoB, RhoC, Rac1, Rac2, Rac3, Cdc42,
RhoH and RhoG, and for a few regulators and eﬀectors.
The generation of cancer-speciﬁc models in mice will help to
elucidate how these proteins work in cancer.
Most of what is known regarding the role of Rho GTPases
in cancer cell invasion has come from the study of the proto-
typic members RhoA, Rac1 and Cdc42 and RhoC, but little
is known regarding other members of the family although they
are known to aﬀect the actin cytoskeleton, and thus further
studies are needed to clarify the roles of these less-character-
ized family members in tumourigenesis in vivo.
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